跳至主要内容
临床试验/DRKS00007822
DRKS00007822已完成不适用

on-interventional study to evaluate neurotoxicity under adjuvant or palliative therapy with Oxaliplatin Omnicare for patients with colorectal carcinoma - NEMO

OMNICARE Pharma GmbH0 个研究点目标入组 179 人开始时间: 2015年3月4日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
179

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • 1.Male and female patients = 18 years
  • 2.Diagnosis of metastatic colorectal carcinoma for which a palliative chemotherapy is indicated or of a colon carcinoma of stage III (Dukes C) after complete resection of the primary tumor for which an adjuvant chemotherapy is indicated
  • 3.Investigator's decision (independent of study participation) to treat the patient with Oxaliplatin Omnicare®
  • 4.Sufficient patient's compliance upon investigator's assessment
  • 5.Written informed consent of the patient to retrospective and prospective pseudonomized documentation, to forwarding and analysis of the data and to access to the data within monitoring

排除标准

  • 未提供

研究者

相似试验